MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

EW · NYSE

Edwards Lifesciences Corporation

Health Care · Industrial Specialties

Reference price$83.68As of Jul 28, 2026
Market capitalization$48.18B
52-week range$72.30–$96.29
S&P 500 portfolio weight0.07%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$85.00+1.6% vs. reference
Average$102.88+22.9% vs. reference
High$110.00+31.5% vs. reference
16 Buy3 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableSep 2026
Consensus EPS$0.739 estimates
Expected range$0.72–$0.75Low to high EPS
Dec 2026$2.99Street EPS consensus
Dec 2027$3.38Street EPS consensus
Dec 2028$3.79Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+11.5% YoY$6.07B$5.44B
Operating income$1.26B$1.38B
Net income$1.07B$4.17B
Operating cash flow$1.6B$0.54B
Capital expenditures($0.26B)($0.25B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Edwards' Q2 Earnings & Revenues Top Estimates, Stock Rises

MarketBeat

Edwards Lifesciences Q2 Earnings Call Highlights

RTTNews

Edwards Lifesciences Q2 Profit Down; Raises 2026 Sales Outlook

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.